Ligand Pharmaceuticals Inc. (LGND)

NASDAQ: LGND · IEX Real-Time Price · USD
72.66
+2.67 (3.81%)
Dec 2, 2022 4:00 PM EST - Market closed
3.81%
Market Cap 1.18B
Revenue (ttm) 241.67M
Net Income (ttm) -21.29M
Shares Out 16.89M
EPS (ttm) 1.47
PE Ratio 49.43
Forward PE 35.59
Dividend n/a
Ex-Dividend Date n/a
Volume 194,745
Open 69.12
Previous Close 69.99
Day's Range 68.44 - 73.09
52-Week Range 45.27 - 102.83
Beta 1.04
Analysts Buy
Price Target 128.35 (+76.6%)
Earnings Date Nov 7, 2022

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight agai... [Read more]

Industry Biotechnology
IPO Date Nov 18, 1992
CEO John Higgins
Employees 154
Stock Exchange NASDAQ
Ticker Symbol LGND
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for LGND stock is "Buy." The 12-month stock price forecast is 128.35, which is an increase of 76.64% from the latest price.

Price Target
$128.35
(76.64% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ligand to Hold Investor and Analyst Day on December 13

SAN DIEGO--( BUSINESS WIRE )--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St. Regis New York on December 13, 2022, from 11:00 ...

2 weeks ago - Business Wire

OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

EMERYVILLE, Calif.--( BUSINESS WIRE )--OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb wa...

Other symbols: OABI
2 weeks ago - Business Wire

Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook

Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.

3 weeks ago - Zacks Investment Research

Ligand Pharmaceuticals (LGND) Misses Q3 Earnings Estimates

Ligand (LGND) delivered earnings and revenue surprises of -8.89% and 71.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Ligand Reports Third Quarter 2022 Financial Results

SAN DIEGO--(BUSINESS WIRE)-- #earnings--Ligand Reports Third Quarter 2022 Financial Results

3 weeks ago - Business Wire

Ligand Announces Completion of OmniAb Spin-Off

SAN DIEGO--(BUSINESS WIRE)--Ligand Announces Completion of OmniAb Spin-Off

1 month ago - Business Wire

OmniAb Announces Completion of Spin-Off and Business Combination

EMERYVILLE, Calif.

Other symbols: OABI
1 month ago - Business Wire

Ligand Distribution of OmniAb Complete and Business Combination Closed

SAN DIEGO--(BUSINESS WIRE)--Ligand Distribution of OmniAb Complete and Business Combination Closed

1 month ago - Business Wire

Ligand Pharmaceuticals (LGND) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Ligand (LGND) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Ligand to Report Third Quarter Financial Results on November 7

SAN DIEGO--(BUSINESS WIRE)--Ligand to Report Third Quarter Financial Results on November 7

1 month ago - Business Wire

Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Pa...

SAN DIEGO--(BUSINESS WIRE)--Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab)

1 month ago - Business Wire

OmniAb Business Combination Approved by APAC Shareholders

SAN DIEGO--(BUSINESS WIRE)--OmniAb Business Combination Approved by APAC Shareholders

1 month ago - Business Wire

LGND vs. RGEN: Which Stock Is the Better Value Option?

LGND vs. RGEN: Which Stock Is the Better Value Option?

Other symbols: RGEN
1 month ago - Zacks Investment Research

Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - Business Wire

Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off

2 months ago - Business Wire

Ligand (LGND) Down 12% Since Last Earnings Report: Can It Rebound?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Trea...

EMERYVILLE, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the Eur...

3 months ago - Business Wire

Ligand Pharmaceuticals (LGND) Misses Q2 Earnings Estimates

Ligand (LGND) delivered earnings and revenue surprises of -37.04% and 44.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Ligand Reports Second Quarter 2022 Financial Results

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Reports Second Quarter 2022 Financial Results

3 months ago - Business Wire

Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

4 months ago - Business Wire

Ligand to Report Second Quarter Financial Results on August 8

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2022 financial results after the close of the U.S. financial markets on Mon...

4 months ago - Business Wire

Sever Your Ties With These 4 Toxic Stocks to Ward Off Losses

Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time hold the key to protecting your portfolio from big losses.

Other symbols: ORARADI
4 months ago - Zacks Investment Research

Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)--Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors

5 months ago - Business Wire

Ligand (LGND) Down 4.9% Since Last Earnings Report: Can It Rebound?

Ligand (LGND) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research

Spot the Red Flags & Sell These 5 Toxic Stocks Right Away

Detoxify your holdings by steering clear of these five stocks, Alarm.com (ALRM), Ligand (LGND), Radius Global (RADI), ADT Inc. (ADT) and Madison Square (MSGE).

Other symbols: ADTALRMMSGERADI
6 months ago - Zacks Investment Research